Stockscreener 앱 받기
137.44
0.15%
-0.21
시간 외 거래:
132.50
-4.94
-3.59%
전일 마감가:
$137.65
열려 있는:
$136.99
하루 거래량:
1.39M
Relative Volume:
1.34
시가총액:
$13.70B
수익:
$2.68B
순이익/손실:
$428.00M
주가수익비율:
32.82
EPS:
4.1873
순현금흐름:
$593.10M
1주 성능:
-0.30%
1개월 성능:
+1.22%
6개월 성능:
+10.86%
1년 성능:
+17.62%
1일 변동 폭
$135.02
$139.83
1주일 범위
$135.02
$142.82
52주 변동 폭
$84.23
$160.18
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
137.44 | 13.72B | 2.68B | 428.00M | 593.10M | 4.1873 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.28 | 57.18B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.67 | 56.47B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.16B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.31 | 40.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
475.85 | 20.37B | 3.13B | 1.27B | 1.12B | 26.39 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-04-15 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
Neurocrine Biosciences Q4 Earnings Call Highlights - MarketBeat
Neurocrine Q4 2025 slides: INGREZZA, CRENESSITY fuel 22% annual growth - Investing.com India
Earnings call transcript: Neurocrine’s Q4 2025 beats forecasts, stock rises By Investing.com - Investing.com India
Earnings call transcript: Neurocrine’s Q4 2025 beats forecasts, stock rises - Investing.com
Neurocrine (NBIX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates - Yahoo Finance
Neurocrine: Q4 Earnings Snapshot - KVUE
Neurocrine: Fourth Quarter Earnings Overview - Bitget
Neurocrine Biosciences Fiscal Q4 Adjusted Earnings, Revenue Rise; Sets INGREZZA FY Guidance - marketscreener.com
Neurocrine Biosciences beats Q4 expectations, offers cautious 2026 guidance - Investing.com
Neurocrine Biosciences Inc Profit Advances In Q4 - Nasdaq
Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Reports Q4 Revenue $805.5M, vs. FactSet Est of $790.5M - marketscreener.com
Neurocrine Biosciences (NASDAQ: NBIX) posts 2025 INGREZZA surge and details DOJ probe - Stock Titan
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 - PR Newswire
Neurocrine Biosciences Q4 25 Earnings Conference Call At 4:30 PM ET - Nasdaq
Neurocrine earnings in focus as Crenessity launch, Ingrezza rivalry heat up - Investing.com Canada
Wesbanco Bank Inc. Makes New $1.26 Million Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Preview: Neurocrine Biosciences's Earnings - Benzinga
Neurocrine Biosciences (NASDAQ:NBIX) Shareholders Have Earned a 11% CAGR Over the Last Three Years - 富途牛牛
Candriam S.C.A. Sells 10,906 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Azzad Asset Management Inc. ADV Acquires New Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine’s Next VMAT2 Study Adds Depth To Tardive Dyskinesia Story - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Cardinal Health (CAH) - The Globe and Mail
The Bull Case For Neurocrine Biosciences (NBIX) Could Change Following Its Next-Gen VMAT2 Phase 2 Trial - Yahoo Finance
Neurocrine’s New Tardive Dyskinesia Trial And What It Means For Valuation - simplywall.st
Exploring Analyst Estimates for Neurocrine (NBIX) Q4 Earnings, Beyond Revenue and EPS - Yahoo Finance
Neurocrine Biosciences, Inc. $NBIX Shares Acquired by Savant Capital LLC - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Principal Financial Group Inc. - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by C WorldWide Group Holding A S - MarketBeat
Will Neurocrine Biosciences Inc. stock pay special dividendsJuly 2025 Snapshot & Accurate Buy Signal Notifications - mfd.ru
Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? - Finviz
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Mediolanum International Funds Ltd Sells 15,811 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
National Pension Service Acquires Shares of 9,951 Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX) Projected to Post Earnings on Wednesday - MarketBeat
Trading the Move, Not the Narrative: (NBIX) Edition - Stock Traders Daily
Short Interest in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Declines By 13.9% - MarketBeat
How Investors Are Reacting To Neurocrine Biosciences (NBIX) Launching Phase 2 Trial For Longer-Acting TD Drug - simplywall.st
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a 31.99% Upside Potential for Investors - DirectorsTalk Interviews
Bank of New York Mellon Corp Has $106.89 Million Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Thrivent Financial for Lutherans Sells 215,514 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Atle Fund Management AB Has $14.41 Million Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX) Valuation Check After New Mid Stage VMAT2 Inhibitor Trial Update - simplywall.st
Y Intercept Hong Kong Ltd Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup - Chartmill
AlphaQuest LLC Boosts Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Downgraded to Buy Rating by Wall Street Zen - MarketBeat
Stifel reiterates Buy rating on Neurocrine Bio stock ahead of Q4 results - Investing.com Canada
Summit Global Investments Boosts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
21,000 Shares in Neurocrine Biosciences, Inc. $NBIX Bought by Hussman Strategic Advisors Inc. - MarketBeat
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
자본화:
|
볼륨(24시간):